Case Reports in Hematology / 2011 / Article / Fig 2

Case Report

Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation

Figure 2

Clinical course. Disseminated intravascular coagulation, DIC, was diagnosed on February 5 in 2010 (the 1st hospital day, day 1), then 25,600 units of recombinant thrombomodulin α (Recomodulin) were administered for 6 days. Additional antithrombin III agent was also supplied on days 4 and 5. Several DIC markers rapidly improved on day 6, and bleeding tendency controlled effectively after Recomodulin administration. Adequate times of platelets transfusion (PC transfusion) were needed to overcome DIC or bone marrow suppression after chemotherapy. Patient achieved the 1st complete remission, CR on Mar. 11 in 2010 (day 35). Then, patient has completed 4 courses of consolidation chemotherapy, and the 1st CR has maintained until the present day.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.